glp 1 agonist inflammation GLP-1 drugs calm beyond diabetes and weight loss 2024 Multiple Sclerosis Highlight -
Description
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial
Serious side effects are uncommon but can include pancreatitis or dehydration if dosing guidelines aren't followed
Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology
Effects on adipose tissue GIPRs are abundant in adipose tissue (170)
